Safety and efficacy of toripalimab plus concurrent chemoradiotherapy for locally advanced cervical cancer: a single-arm, phase Ib trial
Combining toripalimab with CCRT had promising activity in LACC patients but might aggravate radiation-related adverse events and even cause serious immune-related adverse events. Therefore, ICIs therapy with CCRT needs further investigation.
Authors
- Ailin Qu
- Shuhua Wei (ORCID: https://orcid.org/0000-0002-9286-1590)
- Hongyan Guo (ORCID: https://orcid.org/0000-0001-6917-5341)
- Hongbo Chen (ORCID: https://orcid.org/0000-0002-0389-7875)
- Chunxiao Li (ORCID: https://orcid.org/0000-0002-1805-140X)
- Hua Zhang (ORCID: https://orcid.org/0000-0002-5657-5052)
- Junjie Wang (ORCID: https://orcid.org/0000-0003-2264-6745)
- Ping Jiang (ORCID: https://orcid.org/0000-0002-6247-4477)
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12885-025-15059-y
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Junshi Biosciences
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Peking University